Tags

Type your tag names separated by a space and hit enter

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Int J Geriatr Psychiatry 2015; 30(5):505-13IJ

Abstract

OBJECTIVE

We compared amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) in subjects clinically diagnosed with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC) in order to test how these imaging biomarkers represent cognitive decline in AD.

METHODS

Fifteen OHC, 19 patients with MCI, and 19 patients with AD were examined by [(18)F]florbetapir PET to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI and the voxel-based specific regional analysis system for AD to calculate z-score as the degree of entorhinal cortex atrophy, and by mini-mental state examination (MMSE) and Alzheimer's Disease Assessment Scale-cognitive component--Japanese version (ADAS-Jcog) for cognitive functions.

RESULTS

Both cutoff values for measuring AD-like levels of amyloid (1.099 for SUVR) and entorhinal cortex atrophy (1.60 for z-score) were well differentially diagnosed and clinically defined AD from OHC (84.2% for SUVR and 86.7% for z-score). Subgroup analysis based on beta-amyloid positivity revealed that z-score significantly correlated with MMSE (r = -0.626, p < 0.01) and ADAS-Jcog (r = 0.691, p < 0.01) only among subjects with beta-amyloid.

CONCLUSIONS

This is the first study to compare [(18)F]florbetapir PET and MRI voxel-based analysis of entorhinal cortex atrophy for AD. Both [(18)F]florbetapir PET and MRI detected changes in AD compared with OHC. Considering that entorhinal cortex atrophy correlated well with cognitive decline only among subjects with beta-amyloid, [18F]florbetapir PET makes it possible to detect AD pathology in the early stage, whereas MRI morphometry for subjects with beta-amyloid provides a good biomarker to assess the severity of AD in the later stage.

Authors+Show Affiliations

Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25043833

Citation

Tateno, Amane, et al. "Comparison of Imaging Biomarkers for Alzheimer's Disease: Amyloid Imaging With [18F]florbetapir Positron Emission Tomography and Magnetic Resonance Imaging Voxel-based Analysis for Entorhinal Cortex Atrophy." International Journal of Geriatric Psychiatry, vol. 30, no. 5, 2015, pp. 505-13.
Tateno A, Sakayori T, Kawashima Y, et al. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Int J Geriatr Psychiatry. 2015;30(5):505-13.
Tateno, A., Sakayori, T., Kawashima, Y., Higuchi, M., Suhara, T., Mizumura, S., ... Okubo, Y. (2015). Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. International Journal of Geriatric Psychiatry, 30(5), pp. 505-13. doi:10.1002/gps.4173.
Tateno A, et al. Comparison of Imaging Biomarkers for Alzheimer's Disease: Amyloid Imaging With [18F]florbetapir Positron Emission Tomography and Magnetic Resonance Imaging Voxel-based Analysis for Entorhinal Cortex Atrophy. Int J Geriatr Psychiatry. 2015;30(5):505-13. PubMed PMID: 25043833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. AU - Tateno,Amane, AU - Sakayori,Takeshi, AU - Kawashima,Yoshitaka, AU - Higuchi,Makoto, AU - Suhara,Tetsuya, AU - Mizumura,Sunao, AU - Mintun,Mark A, AU - Skovronsky,Daniel M, AU - Honjo,Kazuyoshi, AU - Ishihara,Keiichi, AU - Kumita,Shinichiro, AU - Suzuki,Hidenori, AU - Okubo,Yoshiro, Y1 - 2014/07/07/ PY - 2014/04/02/received PY - 2014/06/06/revised PY - 2014/06/06/accepted PY - 2014/7/22/entrez PY - 2014/7/22/pubmed PY - 2016/1/16/medline KW - Alzheimer's disease KW - beta-amyloid KW - brain atrophy KW - cognitive function KW - positron emission tomography SP - 505 EP - 13 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 30 IS - 5 N2 - OBJECTIVE: We compared amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) in subjects clinically diagnosed with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC) in order to test how these imaging biomarkers represent cognitive decline in AD. METHODS: Fifteen OHC, 19 patients with MCI, and 19 patients with AD were examined by [(18)F]florbetapir PET to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI and the voxel-based specific regional analysis system for AD to calculate z-score as the degree of entorhinal cortex atrophy, and by mini-mental state examination (MMSE) and Alzheimer's Disease Assessment Scale-cognitive component--Japanese version (ADAS-Jcog) for cognitive functions. RESULTS: Both cutoff values for measuring AD-like levels of amyloid (1.099 for SUVR) and entorhinal cortex atrophy (1.60 for z-score) were well differentially diagnosed and clinically defined AD from OHC (84.2% for SUVR and 86.7% for z-score). Subgroup analysis based on beta-amyloid positivity revealed that z-score significantly correlated with MMSE (r = -0.626, p < 0.01) and ADAS-Jcog (r = 0.691, p < 0.01) only among subjects with beta-amyloid. CONCLUSIONS: This is the first study to compare [(18)F]florbetapir PET and MRI voxel-based analysis of entorhinal cortex atrophy for AD. Both [(18)F]florbetapir PET and MRI detected changes in AD compared with OHC. Considering that entorhinal cortex atrophy correlated well with cognitive decline only among subjects with beta-amyloid, [18F]florbetapir PET makes it possible to detect AD pathology in the early stage, whereas MRI morphometry for subjects with beta-amyloid provides a good biomarker to assess the severity of AD in the later stage. SN - 1099-1166 UR - https://www.unboundmedicine.com/medline/citation/25043833/Comparison_of_imaging_biomarkers_for_Alzheimer's_disease:_amyloid_imaging_with_[18F]florbetapir_positron_emission_tomography_and_magnetic_resonance_imaging_voxel_based_analysis_for_entorhinal_cortex_atrophy_ L2 - https://doi.org/10.1002/gps.4173 DB - PRIME DP - Unbound Medicine ER -